A total of 494,189 men and women aged 20 to 70 years without diabetes and with no history of cancer were followed to evaluate cancer and diabetes development.
After adjusting for confounding factors,a significantly decreased risk for subsequent AD was reported among patients with malignant melanoma.
A study presented at the 2018 ASCO Annual Meeting investigated the mortality risk for patients with multiple myeloma who develop VTE.
Long-term neurotoxicity was more frequently seen with cisplatin than with vinca alkaloids, data indicates.
Faced with an increasing CLABSI rate on their oncology unit, nurse leaders at this rural Northwest hospital surveyed their staff to identify the changes they needed to make. Implementing those changes resulted in a dramatic improvement in patient care outcomes.
[Cancer Management and Research] The presence of comorbidities is thought to play a significant role in the decision to treat patients with NSCLC, and this impacts survival.
Independent of cardiovascular risk factors, a history of cancer is a significant factor in future longevity.
Idiopathic thrombocytopenic purpura (ITP) may be linked to an increased risk of cardiovascular disease, but studies have not been conclusive.
Publication of the JNC 8 introduces a lower threshold for initiating hypertension treatment during cancer therapy.
In a secondary analysis of the BEATE and INVEST study, researchers followed a link between levothyroxine use, exercise, and fatigue in women with breast cancer undergoing chemotherapy.
In this retrospective study, researchers sought to determine if cancer patients with rheumatologic disease would be able to tolerate cancer treatment with immune checkpoint inhibitors or if these agents would induce a rheumatologic disease flare.
In this study, researchers sought to determine the effect depressive symptoms during treatment planning had on immediate and long-term outcomes for patients with head and neck cancer.
A literature sought to identify which signs and symptoms in patients with new cancer diagnoses indicate a greater likelihood for long-term emotional distress.
What are the common oncologic emergencies seen in patients with MM?
In a retrospective study of SEER-Medicare data, researchers determined the survival outcomes of women with breast cancer and comorbid mental illness vs those without mental illness.
Researchers conducted a geriatric assessment of 304 patients with cancer, then followed them in a 2-year study to determine the risk of fractures and falls in older patients.
In this case, a female patient with advanced lung cancer experiences a rare episode of nivolumab-induced Herzmyasthenie, emphasizing the need to be aware of the potential for rapid myocarditis concomitant with MG in patients undergoing treatment with anti-PD-1 monoclonal antibodies.
This case of a 63-year-old African American male with a complicated history illustrates the need for a comprehensive risk assessment of thrombosis in patients with primary polycythemia vera, especially those with concomitant conditions that predispose to thrombosis.
Retrospective analysis of data from more than 19,000 women revealed that all-cause mortality rates are higher in women with breast cancer who have a prior diagnosis of a mental illness.
HIV infection may not have a contributory effect on the incidence of invasive cervical cancer (ICC) in women as they age.
Results of a recent study found that the effectiveness of the 9-item Patient Health Questionnaire (PHQ-9) and the Hospital Anxiety and Depression Scale (HADS-D) in screening for major depressive disorder (MDD) in patients with cancer was limited compared to the standardized diagnostic interview.
Cancer rates among people with HIV, particularly AIDS-defining cancers, are projected to decrease by 2030.
A case of simultaneous PAP and MPN diagnoses demonstrate the importance of evaluating for GM-CSF autoantibodies to distinguish autoimmune and secondary forms of PAP.
Genetic Underpinnings of Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms May Provide New InsightsApril 19, 2017
Risk factors for splanchnic vein thrombosis in patients with myeloproliferative neoplasms are multifactorial, involving both environmental and host genetic factors.
Presence of 1 risk factor or 2 or more risk factors is associated with non-home discharge after hysterectomy for gynecologic malignancy.
Twenty-three percent of patients with HNSCC had CVD at the time of their diagnosis.
The risk of developing cancer increases in people who experience heart failure after their first heart attack compared with people who experience no heart failure after their first heart attack.
Likelihood of other chronic conditions will stress health care system in next two decades, as more patients with cancer live longer.
Recent results from a multicenter, phase 2 trial suggest that patients with HIV and aggressive lymphoma should receive autologous stem cell transplant as standard of care. Risk of serious complications after transplant in these patients is equal to that of patients without HIV.
Serious mental illness can both challenge and compromise cancer care. To ensure these patients receive optimal cancer care, the oncology team should include the patient's mental health care team.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Prognostic Factors for Survival Among Patients With Primary Bone Sarcomas of Small Bones
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- A Call for More Tailored Cancer Education Programs to Improve Screening
- Aligning Patient Goals With End of Life Treatment Decisions
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|